Search or Ask Iris
Ctrl+K
Welcome to Multibagg AI
Log in to access personalized features
Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Accretion Pharmaceuticals Limited, established in 2012 as a partnership and incorporated as a public limited company in 2023, is a pharmaceutical manufacturer based in Ahmedabad, Gujarat. The company produces a diverse portfolio of products including tablets, capsules, oral liquids, and external preparations. Accretion Pharmaceuticals serves both domestic and international markets through direct sales and contract manufacturing for various corporate clients. The company is committed to high standards, holding ISO 9001:2015, ISO 14001:2015, and ISO 22000:2018 certifications.
Jan 28, 2026
Jan 30, 2026
Feb 04, 2026
SME
Closed
24.77 Cr
24.77 Cr
0 Cr
₹122 - ₹129
1000
The main objectives of the issue are to utilize the net proceeds for the following purposes:
Funding capital expenditure of Rs. 2.70 crores for purchasing new equipment and machinery to automate testing and packaging processes, thereby increasing production capacity.
Allocating Rs. 4.66 crores for capital expenditure towards upgrading the existing manufacturing facility to meet country-specific audit requirements for expanding into new export markets.
Repayment or prepayment of certain borrowings availed by the company, amounting to Rs. 0.99 crores, to reduce indebtedness and improve the debt-equity ratio.
Funding working capital requirements with an allocation of Rs. 14.68 crores to support business growth for the financial years 2026 and 2027.
Utilizing Rs. 4.43 crores for general corporate purposes, including strategic initiatives, business development, and meeting other operational expenses.
26.27
4.91
68.54%
49.09%
56.5%
—
16.59%
23.36%
7.71
Led by an experienced team of promoters with extensive expertise in the pharmaceutical industry.
Offers a wide and diverse range of products including tablets, capsules, oral liquids, and external preparations.
Maintains strong, long-standing relationships with a broad base of clients and suppliers.
Adherence to high-quality standards, evidenced by ISO 9001:2015 and ISO 14001:2015 certifications.
Significant dependence on top customers, with the top 10 customers accounting for a large portion of revenue.
Business is conducted on a purchase order basis without long-term contracts, leading to revenue uncertainty.
Operations are concentrated in a single manufacturing facility, posing a risk of disruption.
Reliance on third-party providers for carrying out quality testing for its manufactured products.
Expand global footprint by directly exporting products to new and existing international markets.
Leverage government initiatives like the Production Linked Incentive (PLI) scheme to boost domestic manufacturing.
Capitalize on the rapidly growing Indian pharmaceutical market, which is projected to reach $130 billion by 2030.
Utilize the proceeds from the IPO to upgrade manufacturing facilities and increase production capacity.
Faces intense competition from both large, established pharmaceutical companies and unorganized players.
Vulnerability to changes in government regulations and policies in the pharmaceutical sector.
Potential adverse impact from fluctuations in the prices of raw materials and supply chain disruptions.
A slowdown in the Indian or global economy could negatively impact business performance and demand.
Accretion Pharmaceuticals Limited, established in 2012 as a partnership and incorporated as a public limited company in 2023, is a pharmaceutical manufacturer based in Ahmedabad, Gujarat. The company produces a diverse portfolio of products including tablets, capsules, oral liquids, and external preparations. Accretion Pharmaceuticals serves both domestic and international markets through direct sales and contract manufacturing for various corporate clients. The company is committed to high standards, holding ISO 9001:2015, ISO 14001:2015, and ISO 22000:2018 certifications.
The Accretion Nutraveda Ltd. IPO is scheduled to open for subscription on Jan 28, 2026 and close on Jan 30, 2026. Investors can apply for shares during this period through eligible platforms.
The price band for the Accretion Nutraveda Ltd. IPO is ₹122 to ₹129. Investors can place bids within this range once the issue opens.
The minimum lot size for the Accretion Nutraveda Ltd. IPO is 1000 shares. The minimum investment amount ₹1,29,000.
The total issue size of the Accretion Nutraveda Ltd. IPO is approximately ₹24.77. Issue size represents the total value of shares offered to the public.
As per the latest available information, the Accretion Nutraveda Ltd. IPO has been subscribed 0.64 times. Subscription levels can change significantly during the offer period.
The Grey Market Premium (GMP) for the Accretion Nutraveda Ltd. IPO is not available as of now. GMP reflects unofficial market sentiment and should not be considered a guarantee of listing performance.
The shares of Accretion Nutraveda Ltd. are expected to list on stock exchanges on Feb 04, 2026, subject to completion of the allotment process and regulatory approvals.
The net proceeds from the Accretion Nutraveda Ltd. IPO are proposed to be used for The main objectives of the issue are to utilize the net proceeds for the following purposes:, Funding capital expenditure of Rs. 2.70 crores for purchasing new equipment and machinery to automate testing and packaging processes, thereby increasing production capacity., Allocating Rs. 4.66 crores for capital expenditure towards upgrading the existing manufacturing facility to meet country-specific audit requirements for expanding into new export markets., Repayment or prepayment of certain borrowings availed by the company, amounting to Rs. 0.99 crores, to reduce indebtedness and improve the debt-equity ratio., Funding working capital requirements with an allocation of Rs. 14.68 crores to support business growth for the financial years 2026 and 2027., Utilizing Rs. 4.43 crores for general corporate purposes, including strategic initiatives, business development, and meeting other operational expenses.
Before applying for the Accretion Nutraveda Ltd. IPO, investors generally review the company’s business model, financial performance, valuation, industry outlook, and risk factors mentioned in the offer document.
